4 6 6 4 3

论文已发表


注册即可获取德孚的最新动态



IF 收录期刊












更多详情 >>



停止接受任何荟萃分析文章 (Meta-analysis)

请注意:我们所有期刊已于 2019 年 4 月 1 日停止接受任何荟萃分析 (Meta-analysis)文章的提交。


会员计划

我们很高兴为机构提供一种切实的方法以支持开放获取并鼓励教师和研究人员通过开放获取模式尽可能广泛地传播他们的作品。

更多详情 >>

 

视频

Refinement of diagnosis and supporting evidence for the use of immunotherapy through sequential biopsies in a case of EML4-ALK positive lung cancer

 

Authors Song P, Zhang J, Zhang L

Received 28 January 2019

Accepted for publication 12 March 2019

Published 17 April 2019 Volume 2019:12 Pages 2943—2948

DOI https://doi.org/10.2147/OTT.S203192

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Ms Aruna Narula

Peer reviewer comments 2

Editor who approved publication: Dr Tohru Yamada

Abstract: In this case report, we describe a tortuous, yet rare, treatment process of the patient. The first biopsy of the patient suggested inflammatory myofibroblastic tumor, ALK (D5F3) positive. Considering the benign progression of the disease, and no indication for surgical resection, oral prednisone was given first. However, the disease rapidly progressed, and a second biopsy revealed a pulmonary sarcomatoid cancer. Since the biopsy was ALK (D5F3) positive, the effect of crizotinib treatment was significant, though crizotinib resistance unfortunately only occurred after 4 months. The third biopsy pathology was performed and confirmed lung adenocarcinoma. After switching to pembrolizumab treatment, the lesions were significantly reduced after four courses of treatment. The current condition of patient persisted in partial response.
Keywords: sequential biopsies, EML4-ALK, immunotherapy, lung adenocarcinoma


 

摘要视频链接:Immunotherapy for ALK lung cancer